Filing Analysis
OnKure Therapeutics announced a significant repricing of underwater stock options for certain employees and named executive officers. The new exercise price was set at $4.14, significantly lower than the original prices which ranged up to $24.59.
🚩 Red Flags
- Significant repricing of underwater options (often viewed as a dilution/compensation issue that favors insiders).
- Direct benefit to named executive officers including CEO, CMO, and CFO.
- The stock has dropped significantly from its previous highs (original prices up to $24.59 vs new price of $4.14), indicating severe downward pressure on the share price.
📋 Key Facts
- Effective Date: August 7, 2026.
- Repricing target: All outstanding unexercised options granted before Jan 1, 2025, with an exercise price ≥ $10.00.
- New Exercise Price: $4.14 (the closing price on the Effective Date).
- Original Exercise Prices: Ranged from $13.99 to $24.59 per share.
- Total Shares involved: Approximately 1.7 million shares.
- Retention Requirement: Executives must remain with the company for 18 months; others for 12 months, or they forfeit the lower price and revert to original prices.
OnKure Therapeutics, Inc. filed an 8-K to announce its second quarter 2026 financial results and business highlights as of August 4, 2026.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026.
- Filing date: August 4, 2026.
- The filing includes a press release (Exhibit 99.1) detailing financial results and business highlights.
OnKure Therapeutics held its 2026 Annual Meeting of Stockholders on June 3, 2026, resulting in the election of three Class II directors, the ratification of KPMG LLP as the auditor, and the approval of an amended 2024 Equity Incentive Plan.
🚩 Red Flags
- Dilution: The increase in shares reserved for the Equity Incentive Plan (3.2M shares) will result in shareholder dilution.
📋 Key Facts
- Stockholders approved the Amended and Restated 2024 Equity Incentive Plan, which includes a one-time increase of 3,231,638 shares (approx. 8% of outstanding shares).
- The Equity Incentive Plan amendment removes the previous annual limit of 2,407,100 shares while maintaining a 5% annual 'evergreen' increase based on outstanding shares.
- R. Michael Carruthers, Valerie M. Jansen, M.D., Ph.D., and Edward T. Mathers were elected as Class II directors until 2029.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
OnKure Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished under Item 2.02 of the Form 8-K.
📋 Key Facts
- Financial results cover the quarter ended March 31, 2026.
- The report was filed on May 5, 2026.
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Jason Leverone, Chief Financial Officer, signed the filing.
OnKure Therapeutics announced a $150 million private placement of common stock and pre-funded warrants at $4.15 per share. Simultaneously, the company disclosed a major strategic pivot, discontinuing independent development of its lead clinical asset OKI-219 to focus on next-generation candidates with IND filings planned for 2027.
🚩 Red Flags
- Significant dilution from the issuance of over 36 million shares/equivalents.
- Strategic abandonment of the current lead clinical asset (OKI-219) for independent development.
- Long lead time for new pipeline assets, with IND applications not expected until the first half of 2027.
📋 Key Facts
- Entered into a Securities Purchase Agreement for approximately $150 million in gross proceeds.
- Issuing 26,713,636 shares of Class A common stock and 9,430,959 pre-funded warrants at $4.15 per unit.
- Lead investor AI Biotechnology LLC granted a board nominee right; Dr. Liam Ratcliffe appointed to the Board.
- Discontinuing independent clinical development of OKI-219 despite completing enrollment in Phase 1a/1b dose escalation.
- Shifting focus to next-generation PI3Kα pan-mutant programs OKI-345 and OKI-355, with IND applications expected in H1 2027.
- Executive officers and directors entered into 180-day lock-up agreements.
OnKure Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal disclosure of the company's year-end performance via a press release attached as an exhibit.
📋 Key Facts
- The report was filed on March 12, 2026, covering the period ended December 31, 2025.
- The filing includes Item 2.02 (Results of Operations and Financial Condition).
- Jason Leverone, Chief Financial Officer, signed the filing.
- The company is classified as an emerging growth company.
OnKure Therapeutics, Inc. entered into an 'at-the-market' (ATM) sales agreement with Leerink Partners LLC to sell Class A common stock from time to time. This allows the company to raise capital by selling shares directly into the market at prices determined by the company.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of new common stock.
- ATM offerings are often used by micro-cap biotech companies to extend cash runway, which can signal immediate liquidity needs.
📋 Key Facts
- Entered into a Sales Agreement with Leerink Partners LLC on November 6, 2025.
- The program is an 'at-the-market' (ATM) offering under Rule 415 of the Securities Act.
- Leerink Partners will receive compensation of up to 3.0% of gross proceeds.
- Sales are subject to a shelf registration statement on Form S-3 being filed and becoming effective.
- The company maintains discretion to set parameters (max amount, time period, minimum price) and can suspend sales at any time.
OnKure Therapeutics, Inc. filed an 8-K to announce its third quarter 2025 financial results and provide a business update as of November 6, 2025.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025
- Filing date: November 6, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results and business updates.
OnKure Therapeutics, Inc. filed an 8-K to report its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of the company's quarterly earnings and business update.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025
- Filing date: August 12, 2025
- The filing includes a press release titled 'OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update'
- Company is an emerging growth company
OnKure Therapeutics, Inc. filed an 8-K to furnish an updated corporate presentation via its Investor Relations website. This is a routine disclosure under Item 7.01 and does not contain material financial changes or structural shifts.
📋 Key Facts
- The company posted an updated corporate presentation on June 26, 2025.
- The presentation was furnished as Exhibit 99.1 to the report.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
OnKure Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on May 27, 2025. The meeting resulted in the election of two new directors and the ratification of KPMG LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on May 27, 2025.
- Dr. Isaac Manke elected to Class I Board of Directors until the 2028 Annual Meeting.
- Dr. Nicholas Saccomano elected to Class I Board of Directors until the 2028 Annual Meeting.
- KPMG LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2025.
OnKure Therapeutics, Inc. filed an 8-K to announce its first quarter 2025 financial results and recent business highlights as of May 6, 2025.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Filing date: May 6, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial results and business highlights.
OnKure Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024. The filing serves as a formal announcement of the company's periodic earnings release.
📋 Key Facts
- Reporting period: Quarter and Full Year ended December 31, 2024.
- Filing date: March 10, 2025.
- The filing includes a press release (Exhibit 99.1) detailing financial results and business highlights.
OnKure Therapeutics announced preliminary safety, tolerability, and pharmacokinetic data from its first-in-human PIKture-01 trial of OKI-219. The results indicate the drug is well tolerated with no dose-limiting toxicities or significant adverse events reported across 17 patients.
🚩 Red Flags
- The company's forward-looking statements acknowledge significant net losses since inception and the ongoing need to raise additional capital to finance operations.
📋 Key Facts
- PIKture-01 trial (OKI-219) showed no hyperglycemia and only Grade 1 treatment-related adverse events (diarrhea, nausea, pruritus).
- No dose interruptions, delays, reductions, or discontinuations were reported for any adverse events.
- Pharmacokinetic data shows steady-state exposure levels with near-continuous coverage of the in vivo EC80 for pAKT inhibition at 900 mg BID.
- 17 patients have been dosed across three dose levels (300 mg, 600 mg, and 900 mg BID).
- One patient with HR+/HER2- breast cancer showed >95% reduction in PIK3CA H1047R ctDNA and has remained on treatment for over seven months.
- Company expects to provide additional single agent and combination data (with fulvestrant) in the second half of 2025.
OnKure Therapeutics, Inc. has dismissed Ernst & Young LLP (EY) as its independent auditor and appointed KPMG LLP following a recent merger between Reneo Pharmaceuticals and OnKure, Inc. The filing also includes unaudited interim financial statements for the period ended September 30, 2024.
🚩 Red Flags
- Previous audit report (2022) contained a going concern explanatory paragraph.
- Auditor change immediately following a corporate merger can sometimes signal complexities in reconciling different accounting frameworks or reporting standards.
📋 Key Facts
- Dismissal of Ernst & Young LLP (EY) approved by the Audit Committee on November 7, 2024.
- Appointment of KPMG LLP as the new independent registered public accounting firm.
- The company's 2022 audit report contained an explanatory paragraph regarding its ability to continue as a going concern.
- No disagreements with EY were reported regarding accounting principles or auditing procedures.
- Filing includes unaudited interim financial statements and pro forma condensed combined financial information following the merger.
OnKure Therapeutics, Inc. completed a reverse merger with Reneo Pharmaceuticals, Inc., effectively acquiring Legacy OnKure through a combination of a 1:10 reverse stock split and a business combination. The transaction included a $65 million concurrent PIPE investment to provide capital for the combined entity.
🚩 Red Flags
- Reverse stock split (1:10) is often used to maintain Nasdaq listing requirements or consolidate shares.
- Significant net losses incurred by both Reneo and Legacy OnKure since inception.
- High dilution risk for existing shareholders due to the combination of reverse merger, exchange ratios, and a large $65M PIPE issuance.
📋 Key Facts
- Closing Date of merger/transactions: October 4, 2024.
- Reverse Stock Split ratio: 1:10 of Reneo's common stock.
- Concurrent PIPE Investment: Approximately $65.0 million from 'PIPE Investors'.
- Exchange Ratio for Legacy OnKure Common Stock: 0.023596 shares of Class A Common Stock per share.
- Post-transaction outstanding shares: ~12,652,811 Class A Common Stock and 686,527 Class B Common Stock.
- New Ticker Symbol: 'OKUR' on Nasdaq (commenced trading Oct 7, 2024).
- The merger resulted in Legacy OnKure becoming a wholly-owned subsidiary of the Combined Company.
Reneo Pharmaceuticals, Inc. announced that stockholders approved several key proposals at a special meeting on September 26, 2024, primarily centered around a merger with OnKure, Inc. The approval includes the issuance of new common stock and authorization for a reverse stock split.
🚩 Red Flags
- Authorization of a reverse stock split (Proposal 4) is often used to maintain Nasdaq listing compliance following significant share price erosion.
- The merger involves the issuance of shares to PIPE investors, which can lead to significant dilution for existing shareholders.
📋 Key Facts
- Stockholders approved the merger between Reneo Pharmaceuticals and OnKure, Inc., resulting in 'NewCo'.
- Proposal 1 (Nasdaq Rule 5635(a) & (b)) regarding issuance of NewCo Common Stock was approved.
- Proposal 2 (Nasdaq Rule 5635(d)) regarding the issuance of Class A Common Stock to PIPE Investors was approved.
- Proposal 4, which authorizes a reverse stock split at the discretion of the Board, was approved by stockholders.
- The meeting reached a quorum with 21,978,803 shares represented (out of 33,428,808 outstanding).
- Approval was granted for new equity incentive and employee stock purchase plans.
Reneo Pharmaceuticals is voluntarily supplementing its Proxy Statement/Prospectus to address two lawsuits filed in New York alleging misrepresentation of financial projections and conflicts of interest regarding the proposed merger with OnKure, Inc. The company has formed a Special Committee of independent directors to review the transaction following allegations of potential conflicts involving management and placement agents.
🚩 Red Flags
- Active litigation seeking to enjoin/block a major merger transaction.
- Allegations of negligent misrepresentation and concealment regarding financial projections.
- Potential conflicts of interest involving placement agents (Leerink, Evercore, LifeSci) acting in dual roles during the merger process.
- Requirement for a Special Committee due to director affiliations with significant investors.
📋 Key Facts
- Two complaints (Thomas v. Reneo Pharmaceuticals et al. and Kent v. Reneo Pharmaceuticals et al.) filed in NY Supreme Court on Sept 5 and 6, 2024.
- Litigation alleges misrepresentation/omission of material information regarding financial projections and valuation analyses.
- Plaintiffs allege conflicts of interest involving Leerink Partners, Evercore Group L.L.C., and LifeSci Capital LLC in connection with a concurrent private placement.
- The lawsuits seek to enjoin the merger or rescind it if consummated, including claims for punitive damages and legal fees.
- Reneo has formed a Special Committee consisting of Roshawn Blunt, Eric M. Dube, Ph.D., Michael Grey, Paul W. Hoelscher, and Ed Mathers to review the merger terms.
Reneo Pharmaceuticals, Inc. has terminated its Chief Development Officer, Ashley F. Hall, effective September 13, 2024. This departure is linked to a contemplated merger with OnKure, Inc. and the cessation of the company's historical drug development activities.
🚩 Red Flags
- Cessation of historical drug development efforts indicates a fundamental shift in business model or liquidation/merger phase.
- Termination of key executive (Chief Development Officer) during a merger transition.
📋 Key Facts
- Ashley F. Hall, J.D., Chief Development Officer, was terminated effective September 13, 2024.
- The termination is a result of a contemplated merger transaction between Reneo Pharmaceuticals and OnKure, Inc.
- The company is ceasing its historical drug development efforts as part of this strategic shift/merger.
- Ms. Hall will receive severance benefits as previously disclosed in the company's Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
Reneo Pharmaceuticals, Inc. issued a press release reporting financial results for the second quarter ended June 30, 2024, and provided a business update regarding its proposed merger with OnKure, Inc.
🚩 Red Flags
- Significant net losses incurred by both Reneo and OnKure since inception.
- Requirement for additional capital to advance product candidates, which may not be available on favorable terms or at all.
- Risks associated with the timing of closing and potential adjustments to exchange ratios affecting stockholder ownership.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024.
- The filing includes details on the 'Proposed Transactions' involving Reneo and OnKure, Inc., including a concurrent PIPE investment.
- Post-merger management structure: Nicholas A. Saccomano, Ph.D. to become President/CEO; Jason Leverone to become CFO of the combined company.
- The filing serves as solicitation material in connection with the proposed business combination.
Reneo Pharmaceuticals entered into a definitive merger agreement to acquire OnKure, Inc. in a transaction that would result in OnKure stockholders owning approximately 69.4% of the combined company.
🚩 Red Flags
- Reverse stock split proposal included as a required stockholder proposal.
- Significant dilution for existing Reneo stockholders (expected ownership drops to ~30.6%).
- Transaction is highly contingent on securing $60M-$80M in new PIPE funding.
📋 Key Facts
- Merger Agreement signed on May 10, 2024, between Reneo Pharmaceuticals and OnKure, Inc.
- OnKure stockholders expected to own ~69.4% of the combined entity; Reneo stockholders expected to own ~30.6%.
- Valuation: Reneo valued at $75.0 million; OnKure valued at $170.0 million.
- The deal is contingent upon a concurrent PIPE investment of at least $60.0 million (up to $80.0 million).
- Requires stockholder approval for a reverse stock split and name change to 'OnKure Therapeutics, Inc.'
- Post-merger board will consist of 8 members: 6 from OnKure and 2 from Reneo.
Reneo Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly financial results for the first quarter ended March 31, 2024, along with a business update via press release.
📋 Key Facts
- Reporting period: First quarter ended March 31, 2024.
- Filing date: May 7, 2024.
- The filing includes a press release (Exhibit 99.1) containing financial results and a business update.
- Company is an emerging growth company.
Reneo Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2023, alongside a business update.
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2023.
- Filing date: March 28, 2024.
- The filing includes a press release (Exhibit 99.1) containing financial results and a business update.
Reneo Pharmaceuticals is implementing a second workforce reduction of approximately 20% scheduled for February 29, 2024. This action is part of ongoing cost-saving initiatives and will result in estimated charges of $1.7 million in Q1 2024.
🚩 Red Flags
- Significant workforce reduction (20%) suggests ongoing liquidity or operational distress.
- Second consecutive round of layoffs indicates that the initial cost-saving measures may not have been sufficient to stabilize the company's burn rate.
📋 Key Facts
- Second workforce reduction of ~20% to be completed by February 29, 2024.
- Estimated termination costs/severance: approximately $1.7 million.
- Charges are expected to be recognized in the first quarter of 2024.
- Reduction is part of a cost-saving plan originally announced on December 14, 2023.